<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30194203</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>09</Month>            <Day>17</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>17</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1791-7530</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>38</Volume>                    <Issue>9</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                    </PubDate>                </JournalIssue>                <Title>Anticancer research</Title>                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>            </Journal>            <ArticleTitle>Dynamic Contrast-enhanced Magnetic Resonance Imaging for Patients with Breast Cancer Receiving First-line Bevacizumab and Paclitaxel.</ArticleTitle>            <Pagination>                <MedlinePgn>5459-5463</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.12878</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Bevacizumab plus paclitaxel shows promise for metastatic disease; however, there is no predictive biomarker. Dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) is widely used to evaluate the efficacy of anti-angiogenic therapies.</AbstractText>                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Patients with locally advanced/metastatic breast cancer who had not received any prior chemotherapy or hormone therapy were included. DCE-MRI was conducted at baseline and after one and two cycles of bevacizumab and paclitaxel. The percentage change in the volume transfer constant (ΔKtrans) and the correlation of ΔKtrans with tumour regression and time to progression (TTP) were evaluated.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean ΔKtrans from baseline after one and two cycles was -51.4% and -55.1%, respectively. Patients with ΔKtrans ≥50% displayed more tumour regression than those with ΔKtrans &lt;50%; TTP was not significantly different.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We demonstrate a decrease in blood permeability following bevacizumab and paclitaxel using DCE-MRI and a correlation between ΔKtrans and tumour regression.</AbstractText>                <CopyrightInformation>Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Nakatsukasa</LastName>                    <ForeName>Katsuhiko</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan kacchan@koto.kpu-m.ac.jp.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ouchi</LastName>                    <ForeName>Yoshimi</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sakaguchi</LastName>                    <ForeName>Kouichi</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Goto</LastName>                    <ForeName>Mari</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiology, Kyoto Prefectural University of Medicine, Kyoto, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Konishi</LastName>                    <ForeName>Eiichi</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgical Pathology Kyoto Prefectural University of Medicine, Kyoto, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Taguchi</LastName>                    <ForeName>Tetsuya</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016430">Clinical Trial</PublicationType>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>Greece</Country>            <MedlineTA>Anticancer Res</MedlineTA>            <NlmUniqueID>8102988</NlmUniqueID>            <ISSNLinking>0250-7005</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D003287">Contrast Media</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D009942">Organometallic Compounds</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>2S9ZZM9Q9V</RegistryNumber>                <NameOfSubstance UI="D000068258">Bevacizumab</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>6HG8UB2MUY</RegistryNumber>                <NameOfSubstance UI="D008536">Meglumine</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>L0ND3981AG</RegistryNumber>                <NameOfSubstance UI="C072417">gadoterate meglumine</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>P88XT4IS4D</RegistryNumber>                <NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D020533" MajorTopicYN="N">Angiogenesis Inhibitors</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000068258" MajorTopicYN="N">Bevacizumab</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D003287" MajorTopicYN="N">Contrast Media</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D007564" MajorTopicYN="N">Japan</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008279" MajorTopicYN="Y">Magnetic Resonance Imaging</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008536" MajorTopicYN="N">Meglumine</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009942" MajorTopicYN="N">Organometallic Compounds</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D012074" MajorTopicYN="N">Remission Induction</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Advanced breast cancer</Keyword>            <Keyword MajorTopicYN="N">DCE-MRI</Keyword>            <Keyword MajorTopicYN="N">bevacizumab</Keyword>            <Keyword MajorTopicYN="N">paclitaxel</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>06</Month>                <Day>27</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>13</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>17</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>18</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30194203</ArticleId>            <ArticleId IdType="pii">38/9/5459</ArticleId>            <ArticleId IdType="doi">10.21873/anticanres.12878</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>